Introduction
In modern drug development, N-type (Ca v 2.2) and T-type (Ca v 3.1-3.3) calcium channels have been identied as potential analgesic targets. Ziconotide, a specic Ca v 2.2 blocker, was approved by the United States Food and Drug Administration to manage chronic pain through intrathecal administration. 1 Furthermore, CNV2197944 and Z160, another two Ca v 2.2 antagonists, are also in Phase II trials to evaluate their therapeutic effects on chronic pain. In addition, T-type calcium channel inhibitors, such as ABT-639, TTA-P2, KYS-05090S, and Z944, have been proved as antinociceptive agents in different animal models. [2] [3] [4] [5] [6] Specically, Z944, an oral modulator, is in Phase II trials for treating inammatory and neuropathic pain. Valeriana jatamansi Jones (Caprifoliaceae), an annual herb, is mainly distributed in China and mainland India. 7 The roots and rhizomes of this plant are recorded in the Chinese Pharmacopoeia to alleviate gastrointestinal and rheumatic pain. 8 In addition, several clinically used medicines in Chinese market, such as "Xiaoshi Shunqi Pian" and "Xiangguo Jianxiao Pian", are using the extracts of roots and rhizomes of V. jatamansi as a main component to treat gastrointestinal pain. Thus, it is of interest to explore whether the chemical constituents of V. jatamansi have inhibitory effects on N-type or T-type calcium channels.
In the present study, three new valepotriates, velerivaltrates A (1), B (2) and C (3), together with ten known compounds (4-13) were isolated from roots and rhizomes of V. jatamansi (Fig. 1) . Further biological evaluation revealed that all of compounds, except 13, indicated week to noticeable inhibitions on Ca v 2.2 peak currents at 30 mM. Of these compounds, 1, 6, 7, 11 and 12 are potent inhibitors with EC 50 values ranging from 1.13 to 7.8 mM. In addition, these compounds also exhibited 18.2 AE 2.5% to 49.2 AE 7.1% peak current inhibitions on Ca v 3.1 at 30 mM. Finally, specicity study revealed that aforementioned compounds showed apparent selectivity against Ca v 1.2, Ca v 2.1, and KCNH2 (hERG) channels. Described herein are the isolation, structure elucidation, and biological activities of these compounds. C NMR spectra (Tables 1 and 2 ) of 1 were resemble to those of 10-acetoxy-1-acevaltrate hydrin (14) 9 ( Fig. S1 †) with the major differences for the substituent groups at C-7 and C-10, respectively. The isovalerate group at C-7 and the acetate residue at C-10 in 14 were replaced by a b-OAcisovalerate group and an isovalerate unit in 1, respectively. These deductions were supported by downeld shi of C-3 000 by 53. 4 170.9) located the acetoxyl group at C-11. Similarly, another bOAc-isovalerate group was assigned at C-1 based on the HMBC correlations (Fig. 2) . The relative conguration of 1 was elucidated as follows. The anti-orientation of H-1/H-9 was suggested by a large 3 J H,H (10.1
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Hz), which consistent with that naturally occurring iridoids, H-1 is a-oriented and H-9 is b-oriented. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] In the ROESY spectrum ( Fig. 2) , correlations of H-10a and 10b to H-9, but not to H-1, were observed, which helped to establish the b-orientation of C-10. In contrast, correlation of H-7 and H-10 was absence in the ROESY spectrum, which revealed the orientation of H-7 as a.
Comparison of the relative congurations, the experimental OR value, NMR data, as well as the biogenetic ground of 1 with those reported valepotriates 9-18 indicated 1 be in agreement with the 1S, 7S, 8R and 9S conguration. Thus, the structure of 1 was determined as shown and named as velerivaltrate A. (Table 2) exhibited 27 carbon signals, including seven methyls, ve methylenes (one oxygenated), and eight methines (four oxygenated), as well as seven quaternary carbons (four ester C]O groups and three oxygenated ones). Taken together, these data indicated that, structurally, 3 was similar to chlorovaltrate A (15), 11 ( Fig. S1 †) with the major differences for the substituent groups at C-4 and C-7. In 3, a chlorine atom substituted at C-4 (d C 73.8, s) and an acetylated methylene replaced the terminal olenic bond at C-4 of 15. These elucidations were conrmed by its molecular formula and HMBC correlations of H-11 (4 The relative conguration of the core structure of 3 was established by the ROESY experiment. The cross-peaks of H-9 (biogenetically b-oriented) with H-10 and H-3 indicated the aorientation of the oxo-bridge from C-3 to C-8. Similarly, the ROESY correlations of H-6a to H-7 indicated H-7 was a-oriented. Besides, the correlation between H-9/H-11 revealed the b-orientation of the acetylated methylene at C-4. The orientation of OH-5 was deduced as b on the basis of the comparison of the spectroscopic data of 3 with those reported chlorinated valepotriates and the molecular modeling with a rigid epoxy-bridge skeleton. 10, 11, 13 The conguration of C-1, C-3, C-4, C-5, C-7, C-8 and C-9 were determine as S, R, S, R, S, S, and S, respectively, by the same way as that of 1. Consequently, the structure of 3 was elucidated and named as velerivaltrate C.
The known compounds were determined as valtrate hydrin B1 (4) and valeriananoid C (13) 24 by comparison their spectroscopic data with those reported in the literature.
All of the isolated compounds (1-13) were evaluated their inhibitory effects on Ca v 2.2 and Ca v 3.1 calcium channels by twoelectrode voltage clamp (the positive control u-conotoxin MVIIA for Ca v 2.2 and mibefradil for Ca v 3.1 showed strong inhibitions at 200 nM and 30 mM, respectively Fig. S42 †) . As a result, compound 1-12 apparently inhibited Ca v 2.2 peak currents ranging from 23.6 AE 2.5% to 63.9 AE 3.9% at the concentration of 30 mM (Table  3) . Of these, compounds 1, 6, 7, 11 and 12 were the most potent inhibitors, with EC 50 values of 4.33, 2.18, 1.13, 2.70 and 7.8 mM, respectively. Interestingly, the inhibition by these compounds was incomplete, plateauing at $60% by a near saturation concentration of 30 mM (Fig. 3) . This result suggests that compounds 1, 6, 7, 11 and 12 act allosterically to modulate Ca V 2.2 gating rather than block channel conduction. On the other hand, compounds 1, 4, 5, 6, 7, 9, 10, 11, and 12 obviously showed peak current inhibitions on Ca v 3.1 at 30 mM (inhibition ratio between 18.2 AE 2.5% to 49.2 AE 7.1%, Table 3 ). Among them, compounds 1, 4, 7, 9, 11 and 12 presented potent inhibitory effects on Ca v 3.1 with a roughly average value of 42% (Table 3 ). In addition, we also tested the antagonistic effects of compounds 1-12 on several other types of voltage-gated ion channels, including L-type (Ca v 1.2), P/Q-type (Ca v 2.1) and KCNH2 (hERG). Signicantly, aforementioned compounds exhibited weaker or no effect on those channels (Table 3 and Fig. 3 ).
Conclusions
In summary, our study shows that valepotriates, the main constituents of the V. Jatamansi, can selectively inhibit Ca v 2.2 and Ca v 3.1 calcium channels, which consistent with the analgesic effect of this herb medicine in alleviating gastrointestinal and rheumatic pain. This discovery not only gives the potential clue of the active constituents responsible for the traditional use of V. Jatamansi but also afford a new structural prototype of Ca v 2.2 and Ca v 3.1 dual-inhibitor. In future, bioassay-guided investigations on V. Jatamansi may yield more specic and potent compounds that target N-type and T-type calcium channels.
Experimental section

General experimental procedures
Column chromatography (CC) was run on Silica gel (200-300 mesh, Qingdao Marine Chemical, Inc.), Lichroprep RP-18 (40-63 mm, Merck), MCI gel (75-150 mm, Mitsubishi Chemical Corporation, Japan), and Sephadex LH-20 (Amersham Biosciences, Sweden). Fractions were monitored by TLC (silica gel 60 F 254 , Qingdao Marine Chemical, Inc.) using various solvent systems, and spots were visualized by UV light (254 nm) and sprayed with 5% sulfuric acid in EtOH, followed by heating. Semipreparative HPLC was carried out on an Agilent 1100 liquid chromatography system using an YMC-Pack 10 mm Â 250 mm column (Pro C18 RS). All currents were recorded with an OC- All the data were analyzed with two-tailed student T test and represented as mean AE SEM (n ¼ 3), *P < 0.05, **P < 0.01, compared with blank control.
725C Oocyte Clamp (Warner Instrument Corp.) and digitized by Digidata 1440A (Molecular Devices). Optical rotations were recorded on a JASCO model 1020 polarimeter (Horiba, Tokyo, Japan). IR (KBr) spectra were obtained using a Tenor 27 spectrophotometer (Bruker Optics GmbH, Ettlingen, Germany). UV spectra were measured on a Shimadzu UV-2401PC spectrophotometer (Shimadzu, Kyoto, Japan). 1D and 2D NMR spectra were performed on a Bruker Avance III 600 spectrometer (Bruker, Bremerhaven, Germany). Chemical shis (d) are expressed in ppm with reference to the solvent signals. ESIMS and HRESIMS were run on a Shimadzu LCMS-IT-TOF mass spectrometer (Shimadzu, Kyoto, Japan) or an Agilent G6230 TOF MS (Agilent Technologies, Palo Alto, USA) or an API QSTAR time-of-ight (AB-MDS Sciex, Concord, ON, Canada).
Plant material
The roots of V. Jatamansi were purchased in July 2012 from Yunnan Hongxiang Yixintang Pharmaceutical Co., Ltd. and identied by Dr Zhi-Kun Wu. A voucher specimen (KUN no. 0864803) has been deposited at Herbarium of Kunming Institute of Botany, the Chinese Academy of Sciences, Kunming, China. 
